Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine, Amoxicillin, and Vonoprazan Triple Therapy for H. Pylori
NCT05014334Phase 4Completed
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of berberine in Helicobacter pylori infection (3 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Helicobacter pylori eradication rates. Started Dec 2021; status: completed.
02
Drugs
berberine
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05014334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014334.